Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
May 03 2023 - 8:30AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a leading T-cell receptor (TCR) cell therapy company
advancing a clinical-stage pipeline of therapeutics for solid
tumors, today announced that it will report financial results for
the first quarter ended March 31, 2023, on Wednesday, May 10, 2023,
before the open of U.S. markets. Following the announcement, the
Company will host a conference call and webcast at 9:00 a.m. ET to
review the financial results and provide a corporate update.
Register for the live webcast using the link
here or by visiting the “Investors” section of the Alaunos website
at www.alaunos.com. To participate via telephone, please register
in advance at this link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. The event will be archived on the Company’s website for
approximately 30 days after the call.
About Alaunos Therapeutics,
Inc.Alaunos Therapeutics is a leader in the science of
T-cell receptor (TCR) cell therapy working to revolutionize solid
cancer treatment and outcomes. The clinical-stage company’s TCR
T-cell therapy (TCR-T) is one of the most advanced TCR programs
targeting driver mutations in solid tumors with an ongoing Phase
1/2 trial of its TCR-T product candidates across six solid cancers.
Alaunos is powered by two proprietary platforms: its elegantly
efficient non-viral Sleeping Beauty cell engineering platform; and
its hunTR® discovery platform, which is expanding its
industry-leading library of TCRs against high-frequency driver
mutations. Alaunos is a part of an ongoing collaboration with the
National Cancer Institute (NCI), part of the National Institutes of
Health (NIH), working to advance the science of TCR therapy. For
more information, visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Media Contact:Heather Anderson6
Degrees PRhanderson@6degreespr.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024